Credits: Canva
Many of us may have taken ibuprofen, sometimes two pills at once, especially when we are struggling with menstrual cramps. Well, as good these pills may be in treating the pain, they are not recommended for your health, especially if you are someone who consumes it on a daily basis or frequently. Gastroenterologist Trisha Pasricha, MD, writes in The Washington Post about why should you avoid taking nonsteroidal anti-inflammatory drugs, or NSAIDs, such as ibuprofen, naproxen and aspirin.
She writes that NSAIDs are great in treating short term pain. They comprise of a group of drugs that inhibit the production of prostaglandins, which serve as a variety of purposes in the body. Some of which also includes contracting the uterus during menses and regulating blood flow in our vessels.
While one to two doses every now and then is okay, following a regular dosage routine, which could range from several times a month, or twice in an hour or so could lead to health risk. NSAIDs are well known to increase intestinal permeability. This means, these painkillers could damage the lining of your gut.
A 2018 review by Ingvar Bjarnason et. al., also writes about how NSAIDs can reduce the blood flow in the tiny vessels that feeds our guts. It can also disrupt the intestinal cells forming a barrier between the outside world and your insides.
While people with conditions like migraines, chronic back pain or bad period cramps can find NSAIDs to be helpful. It is always advisable to have a chat with your physicians to explore NSAID alternatives.
Pasricha suggests acetaminophen.
However, if someone is in dire need of NSAID, her tip is to take the pill right at the start of your symptoms. She says that the drug can do a far better job at stopping things at the source than chasing after all prostaglandins.
NSAIDs are available as over the counter drug, which means people do not need a prescription for it and can make medical decision about them without the guidance of a physician.
A 2018 study published in the Official Journal of the International Society for Pharmacoepidemiology by David W Kaufman, et.al., found that 15% of adult ibuprofen users in the US have exceeded the maximum recommended daily dose. The study also mentions that more than a third of ibuprofen users were taking other NSAIDs, like aspirin and naproxen, while consuming ibuprofen at the same time. Out of these, 61% did not realise that they were using NSAIDs.
Pasricha talks about how it ruptures the gut wall, as she herself has rushed to the hospital in the middle of the night "far more times than" she can count "to perform an emergency endoscopy on someone who was bleeding profusely from an ulcer caused by NSAID".
Another 2009 study published in the American Journal of Gastroenterology states that as many as 1 in 4 chronic NSAID users will get an ulcer and about 4% will bleed or rupture through the gut wall.
An older study from 2005 titled A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy, found that as 75 percent of people regularly using NSAIDs develop low-grade inflammation in their small bowels. NSAIDs can also lead to development of fatty liver disease. This happens because your gut lining becomes more permeable, more toxins and bacteria from the outside world enters your liver and leads to inflammation.
A 2011 study titled Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials, states that as many as 6% of people taking NSAIDs regularly have found their blood count dropping within a few months of starting the medicines, this suggests that this is due to the small, slow amount of bleeding in the gut overtime.
Credit: AI
When we think of dialysis, we often picture a machine filtering blood and keeping patients alive. What rarely comes to mind is the small blood vessel in the arm that makes the entire process possible.
For every patient on haemodialysis, the arteriovenous (AV) fistula is quite literally a lifeline. Without it, dialysis cannot be performed effectively. Yet, despite being one of the most important parts of treatment, fistula care remains one of the least understood aspects of kidney disease.
This silent gap in awareness is costing patients their lifeline.
India adds nearly 2.2 lakh new patients with end-stage kidney disease every year, creating a demand for over 3.4 crore dialysis sessions annually.
One of the biggest challenges we see in clinical practice is that patients often seek medical help only after the fistula has already stopped functioning.
The warning signs are usually ignored.
The vibration over the fistula becomes weaker. The arm begins to swell. Bleeding continues longer than usual after dialysis. Needle insertion becomes increasingly difficult. Sometimes dialysis itself becomes less effective.
By the time patients reach an interventional radiologist or vascular specialist, the fistula may already have developed significant narrowing (stenosis) or complete blockage.
Unfortunately, many of these complications are preventable if detected early.
In our experience, nearly 30% of patients eventually lose their fistula because they report too late, when timely intervention could have salvaged access.
Also read: COVID Spikes In India: Experts Allay Fears, Stress Vaccination And Masks
Unlike diabetes or blood pressure, there is no widespread public awareness around fistula surveillance.
Many dialysis patients receive instructions on medicines and dialysis schedules but very little education on how to examine their fistula every day.
There is also no universally implemented patient education protocol across dialysis centres, leading to inconsistent awareness about fistula care.
The result is simple: patients unknowingly damage the very access that keeps them alive.
Patients should examine their fistula daily.
A healthy fistula has a continuous buzzing sensation or “thrill.” If this vibration becomes weak or disappears, medical attention should be sought immediately.
Similarly, swelling of the arm, redness, prolonged bleeding after dialysis, pain around the fistula, or difficulty during needle insertion should never be dismissed as routine.
These are early warning signs - not inconveniences.
Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring
These small daily habits can often extend the life of a fistula by years.
One of the greatest advances in dialysis access care is that many fistula problems no longer require open surgery.
If narrowing is detected early, minimally invasive image-guided procedures such as fistuloplasty (balloon angioplasty) can restore blood flow, preserve the existing fistula and help patients continue dialysis without interruption.
The key, however, is timing.
A fistula that is evaluated early is often salvageable.
A fistula ignored for weeks may not be.
Every successful fistula represents months of planning, surgery and healing. Losing it means additional procedures, temporary catheters, higher infection risk, increased costs and emotional distress for patients already living with chronic kidney disease.
As doctors, we have become increasingly skilled at creating dialysis access.
The next challenge is ensuring patients know how to protect it.
Because for someone living with kidney failure, the fistula is not just another blood vessel.
It is the lifeline that keeps life moving.
By Dr. Avik Bhattacharyya, Senior Consultant - Interventional Radiology, CK Birla Hospitals, CMRI
Credit: iStock
GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and liraglutide, best known for regulating appetite and aiding weight loss, may also help reduce symptoms of binge eating disorder (BED), which affects more than 17 million people worldwide, according to a new study.
The systematic review and meta-analysis, published in the journal eClinicalMedicine, found that GLP-1 drugs, with semaglutide as its key ingredient, reduced binge eating episodes, loss-of-control eating and emotional eating, highlighting their potential role in treating binge eating disorder alongside obesity.
Binge eating disorder affects over 17 million people globally, and around two-thirds of people with the condition also live with overweight or obesity. It is also common among individuals seeking weight-loss treatment.
"Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide," said lead author Dr Ilaria Costantini from the Psychiatry Department at University College London (UCL), UK.
"But treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition. We found evidence that weight loss drugs may help to manage some key symptoms of binge eating disorder," Costantini added.
Also read: Babies Without Vitamin K Shot At Higher Risk Of Brain Bleeding: Study
The researchers analyzed 25 randomized controlled trials conducted across 12 countries on four continents, involving 8,069 participants.
The trials evaluated GLP-1 drugs that target the appetite-regulating hormone GLP-1, including semaglutide (marketed as Ozempic or Wegovy), tirzepatide (Mounjaro) and liraglutide.
These medications suppress appetite by acting on the central nervous system and insulin secretion, delay stomach emptying, and may also influence brain pathways involved in reward and impulse control.
Compared with placebo or other treatments, people taking GLP-1 drugs reported:
Read More: Obesity-Driven CKM Syndrome A Growing Public Health Threat, Warns American Heart Association
The researchers also found that participants taking GLP-1 drugs reported greater cognitive or dietary restraint, meaning they made more deliberate efforts to limit what they ate.
The benefits extended beyond weight loss, with improvements seen in several behaviors associated with binge eating disorder.
While increased dietary restraint was observed, the researchers cautioned that it remains unclear whether this represents healthy self-regulation or a more rigid, potentially harmful eating pattern that could worsen binge eating over time.
"From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating. We hope that future research can clarify whether or not taking weight loss drugs might contribute to more pathological forms of eating restriction such as meal skipping," said Izzy Emptage from UCL Psychiatry.
The researchers said GLP-1 drugs could become an important addition to treatment plans for binge eating disorder when used alongside psychological therapies and social support.
However, they also highlighted important limitations. Most of the studies included in the review had a high risk of bias, were funded by pharmaceutical companies, and rarely included participants with a clinical diagnosis of binge eating disorder, reducing the certainty of the findings.
"GLP-1s may offer a promising additional treatment option for people living with both binge eating and obesity," the researchers said, while stressing that these drugs "should not be viewed as a standalone solution to binge eating disorder."
They added that larger, independently funded clinical trials are needed before these medications can be routinely recommended for treating binge eating disorders.
Credit: AI
What if staying younger has less to do with expensive anti-aging products and more to do with spending time appreciating the culture. A new study suggests that regular cultural outings may be linked to slower biological aging.
Expect an unexpected addition to the list of healthy lifestyle habits. Researchers recently found that older adults who frequently visited museums, theaters, cinemas, concerts, and art galleries physically functioned as if they were about three years younger than those who didn’t take part in such activities.
Published in the Journal of Epidemiology and Community Health, the researchers say that cultural interaction appears to be associated with a younger physiological age, although the study does not prove that cultural activities directly contribute to slow aging.
The study analyzed data from 1,899 adults aged 50 years and older who participated in the English Longitudinal Study of Ageing. Participants reported how often they:
Researchers also assessed 10 health indicators, including:
These measures were combined to ascertain each participant's physiological age.
People who participated in cultural activities every few months or more had an average physiological age of 66.9 years, compared with 69.9 years among those with lower levels of cultural engagement, a difference of roughly three biological years.
The researchers also found that every one-point increase in a person's cultural engagement score was associated with approximately a 31-day reduction in physiological age, even after accounting for income, employment, and chronic health conditions.
Although the study wasn't designed to identify a direct cause, the researchers suggest several possible explanations that can help reduce biological age. Cultural activities may help:
Interestingly, the researchers noted that the association between cultural engagement and slower aging was comparable to the benefits seen with frequent physical activity, highlighting that healthy aging may involve much more than exercise alone.
The latest findings add to a growing body of research suggesting that spending time on cultural activities may benefit both the brain and the body as people age.
Previous studies have found that older adults who regularly visit museums, art galleries, theaters, concerts, and similar cultural spots may have a lower risk of dementia, experience slower cognitive decline, and even live longer than those who rarely engage in such activities.
For example, a 2019 study published in The BMJ reported that adults over 50 who participated in cultural activities every few months or more had a 31% lower risk of death during a 14-year follow-up compared with those who never took part.
Another study from University College London found that frequent museum visits were associated with a reduced risk of developing dementia over the following decade.
© 2024 Bennett, Coleman & Company Limited